Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on On the Beach

(Sharecast News) - Analysts at Berenberg raised their target price on travel retailer On the Beach from 300p to 330p on Monday following the group's full-year results on 2 December. Berenberg noted that On the Beach's FY25 results had "calmed the market" on the company's outlook, with summer 2026 bookings building momentum and supporting an outlook in line with expectations.

"While the company has a lot to do to reach its medium-term ambition, the business is performing well, both in its core beach business and city breaks and in the Republic of Ireland, and it is continuing to outgrow the market and deliver robust shareholder returns," said Berenberg, which reiterated its 'buy' rating on the stock.

The German bank added that on multiples, On the Beach trades on 10.1x/8.1x its FY26/27 estimates.

Reporing by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Aeorema Communications shares jump on guidance upgrade
(Sharecast News) - Shares in Aeorema Communications jumped on Tuesday after the AIM-listed strategic comms firm hiked its profit guidance for the full year following a strong start to the second half.
Citi lifts price target on Vodafone, maintains 'neutral' rating
(Sharecast News) - Citi lifted its price target on Vodafone on Tuesday to 127p from 110p as it said scope for positive news was stopping it from taking a more cautious stance.
MJ Gleeson swings to full-year loss, cuts dividend
(Sharecast News) - MJ Gleeson said on Tuesday that it swung to a full-year pre-tax loss in a 'subdued' market, as it took a hit from exceptional costs of £13.6m.
Deutsche Bank upgrades Astrazeneca to 'hold'
(Sharecast News) - Deutsche Bank upgraded Astrazeneca from 'sell' to 'hold' on Tuesday and nudged its price target up from 11,500p to 11,700p, saying the risk‑reward scenario had shifted following last week's negative SERENA-4 readout and a period of underperformance against European large‑cap peers.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.